Sandoz Sales Rise 9% to $3.01 Billion in First Half of 2026

Sandoz reported $3.01 billion in sales for the first half of 2026 on 5 August, up 9% and slightly above what analysts expected. The gain came from biosimilars — lower-cost versions of complex biologic drugs. It's the first proof that new launches would lift growth this year, as management predicted in February. Sandoz holds an investor event 8 September in London.